Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Golden Cross könnte Australiens nächste Goldentdeckung in der Pipeline haben!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41HUM | ISIN: US09075X2071 | Ticker-Symbol:
NASDAQ
07.10.25 | 22:00
7,300 US-Dollar
-4,32 % -0,330
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODESIX INC Chart 1 Jahr
5-Tage-Chart
BIODESIX INC 5-Tage-Chart

Aktueller Chart BIODESIX Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
BIODESIX INC-Investoren interessieren sich auch für diese Wertpapiere
ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted...
► Artikel lesen
ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of...
► Artikel lesen
ADMA Biologics, Inc.: ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement ProcessApproval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process...
► Artikel lesen
Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced...
► Artikel lesen
CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006- Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass...
► Artikel lesen
CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ...
► Artikel lesen
CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal...
► Artikel lesen